Roivant Sciences and its subsidiary Priovant reported positive results from two Phase 3 trials, CLARITY-1 and CLARITY-2, testing Lisraya (brepocitinib) for non-infectious uveitis, an inflammatory eye disease that can threaten vision.
Across the trials’ 371 participants, Lisraya significantly delayed treatment failure:
median time exceeded 48 weeks, compared with about 12 weeks on placebo. The drug also met the trials’ key secondary endpoints.
In pooled results, 62% of patients taking Lisraya had steroid-free disease control at week 48, versus 20% on placebo. Among eyes with macular edema at the start, 42% had resolution by week 48, versus 4.8% with placebo.
The findings could put Lisraya in contention with Humira, currently the only FDA-approved systemic biologic specifically for non-infectious uveitis. However, the trials did not directly compare the drugs, so claims of superiority are based on cross-trial comparisons.
Priovant plans to seek an FDA label expansion for uveitis in the first half of 2027. Reports said the trials showed no new safety signals, and about 3% of participants stopped Lisraya because of adverse events.
Sources:
Roivant comes for Humira as Lisraya checks boxes in inflammatory eye disease phase 3s
Roivant says closely watched immune drug succeeded in new eye disease
Roivant eyes Lisraya label expansion on Phase III uveitis win
Priovant Will Seek Expanded Approval of Lisraya After Positive Results in Inflammatory Eye Disease
Roivant, continuing ascent, claims another victory for rare disease drug
GSK picks up hep B drug approval
Why Is Roivant Sciences Stock Surging Wednesday?
Why Is Roivant Sciences Stock Surging Wednesday?
Roivant, Priovant targeting uveitis for next brepocitinib NDA
ROIV News Today | Why did Roivant Sciences stock go up today?
ROIV 8-K Filings - Roivant Sciences Ltd. SEC 8-K
Brepocitinib meets all Phase 3 end points in noninfectious uveitis